MSB 1.34% $1.51 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-708

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 132 Posts.
    lightbulb Created with Sketch. 22
    https://edition.cnn.com/2020/04/22/health/coronavirus-ventilator-patients-die/index.html

    Interesting as I read this study to show a 75% rate of survival of patients on ventilators closely aligned to the mesoblast 12.

    the numbers seem to be moving around a bit. There will be two things to keep a close eye on - more broad data on survival rates of ventilated patients and the mesoblast trial results.

    this shows the importance of the trial and control to determine the effectiveness. Signs are very encouraging but there seems to be a lot of talk around certainty of success on a sample of 12 when compared to the survival rates from two New York hospitals when the numbers in New York State alone seem to be moving around.









 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.